Literature DB >> 90269

Adrenal steroids and the development of osteoporosis in oophorectomised women.

S C Manolagas, D C Anderson, R Lindsay.   

Abstract

To explore the possibility that the wide variation in bone loss among oophorectomised women might be due to differences in adrenal androgens or their biosynthetic pathways, 18 women (10 with very fast and 8 with very slow bone loss) were selected. Serum levels of nine adrenal steroids, including the major androgens and cortisol, were measured under basal conditions and after overnight suppression followed by acute corticotropin stimulation. In addition, basal serum oestrone, oestradiol, dehydroepiandrosterone sulphate, sex-hormone-binding-globulin, corticosteroid binding globulin, and urinary free cortisol were measured. The only significant differences found were that women who lost bone rapidly had significantly higher urinary free-cortisol excretion (p less than 0.001) and a paradoxically diminished cortisol response to corticotropin. These data make it unlikely that endogenous adrenal androgens or oestrogens are a major factor in preventing bone loss after cessation of ovarian function; cortisol by its catabolic effect, however, may be a significant factor in causing osteoporosis.

Entities:  

Keywords:  Adrenal Cortex Hormones--analysis; Androgens--analysis; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Methods--indications; Endocrine System; Estradiol--analysis; Estrogens; Estrone--analysis; Family Planning; Hematological Effects; Hemic System; Hormones; Immunoglobulin Alterations; Oral Contraceptives--indications; Physiology; Research Methodology; Retrospective Studies; Studies

Mesh:

Substances:

Year:  1979        PMID: 90269      PMCID: PMC8334240          DOI: 10.1016/s0140-6736(79)91663-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy.

Authors:  L V Avioli
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

2.  The impact of a new emotional self-management program on stress, emotions, heart rate variability, DHEA and cortisol.

Authors:  R McCraty; B Barrios-Choplin; D Rozman; M Atkinson; A D Watkins
Journal:  Integr Physiol Behav Sci       Date:  1998 Apr-Jun

3.  Bone mineral density in Addison's disease.

Authors:  J P Devogelaer; J Crabbé; C Nagant de Deuxchaisnes
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

Review 4.  Androgens and bone.

Authors:  D Vanderschueren; R Bouillon
Journal:  Calcif Tissue Int       Date:  1995-05       Impact factor: 4.333

5.  Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: evidence that skeletal sensitivity is increased.

Authors:  M A Kotowicz; G G Klee; P C Kao; W M O'Fallon; S F Hodgson; S L Cedel; E F Eriksen; D G Gonchoroff; H L Judd; B L Riggs
Journal:  Osteoporos Int       Date:  1990-10       Impact factor: 4.507

6.  Sex steroids, bone turnover and bone mineral density in pre-, peri-, and postmenopausal women.

Authors:  T Akatsu
Journal:  Environ Health Prev Med       Date:  1998-10       Impact factor: 3.674

7.  Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy.

Authors:  T C Durbridge; H A Morris; A M Parsons; I H Parkinson; R J Moore; S Porter; A G Need; B E Nordin; B Vernon-Roberts
Journal:  Calcif Tissue Int       Date:  1990-12       Impact factor: 4.333

8.  Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.

Authors:  H Rico; A Charro; I Depablos; E Bordiu; E R Hernandez; D Espinos
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

9.  Dehydroepiandrosterone sulphate and bone mineral density.

Authors:  M Szathmári; J Szũcs; T Fehér; I Holló
Journal:  Osteoporos Int       Date:  1994-03       Impact factor: 4.507

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.